Clinical Trials Browser

Phase 2 × dapagliflozin × 30 days × Clear all

NCT06427226 2026-04-17

Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity

Phase 2 Recruiting

Breast Neoplasms